Figure 2.
Figure 2. Changes in bone turnover markers over the study period. Panels A and B show the unadjusted distribution of changes after 12 months in the three dosing groups for the bone formation marker, P1NP and the bone resorption marker, B-CTx, respectively. Only the high-dose group showed significant within-group decreases. Panels C and D depict the mean changes after 12 months in the three dosing groups for P1NP and B-CTx, respectively, after adjusting for race, sex, and the following baseline characteristics: age, body mass index (BMI), Tanner stage (5 vs. <5) and HIV-1 RNA (<80 vs. ≥80 copies/mL). *P value for differences in changes among the three dosing groups; **P value for changes within the high-dose group; †P values for the difference in changes between the high- and standard-dose groups. N.B. One outlier from each plot in A and B was removed for better visualization but was included in the calculations. The upper limit of detection for P1NP was 300 ng/mL, and those subjects with an unmeasurable value above the upper limit were assigned a value of 300 ng/mL for the purpose of calculation of change from baseline. P1NP, procollagen type 1 amino-terminal propeptide; B-CTx, B-CrossLaps